Karla Guadalupe Del Castillo Loreto

Ms. Karla Guadalupe Del Castillo Loreto

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2024 in Nutrients
Verified
Journal Article
Open access
PDF file
LCLABORATORIOS COLUMBIA COMERCIAL
LABORATORIOS COLUMBIA COMERCIAL
ECEnrique Carmona-Montesinos
Enrique Carmona-Montesinos
GCGilberto Castañeda-Hernandez
Gilberto Castañeda-Hernandez
ICIsrael Campos
Israel Campos
Juan Carlos Castillo SalinasJuan Carlos Castillo Salinas
Juan Carlos Castillo Salinas
EREdgar Ramirez-Ramirez
Edgar Ramirez-Ramirez
Background: Current treatment for chronic kidney disease (CKD) focuses on improving manifestations and delaying progression. Nutritional approaches play a crucial role in CKD management, and various supplements have become available. Ketoanalogues of amino acids (KAs), calcium citrate, and inulin have been proposed as suitable supplements, yet their widespread use has been limited due to insufficient evidence. This study aimed to generate general guidance statements on the appropriateness of these supplements through a RAND/UCLA consensus process. Methods: A RAND/UCLA consensus panel was convened to evaluate the appropriateness of these supplements in different clinical scenarios. In this study, we present a subgroup analysis focusing on a panel of eleven clinical nephrologists from among the experts. Results: Supplementation of low-protein diets (LPDs) and very low-protein diets (VLPDs) with KA was considered appropriate to reduce manifestations and delay CKD outcomes, supplementation with calcium citrate is considered appropriate to reduce CKD manifestations, and supplementation with inulin is considered appropriate to delay CKD outcomes and manage comorbidities. Conclusions: Based on a combination of clinical experience and scientific evidence, the panel reached a consensus that KA supplementation of LPD and VLPD, calcium citrate, and inulin are appropriate in patients with CKD across various scenarios.

12 August 2024 in Preprints.org
Verified
Preprint
Open access
PDF file
LCLABORATORIOS COLUMBIA COMERCIAL
LABORATORIOS COLUMBIA COMERCIAL
ECEnrique Carmona-Montesinos
Enrique Carmona-Montesinos
GCGilberto Castañeda-Hernandez
Gilberto Castañeda-Hernandez
ICIsrael Campos
Israel Campos
Juan Carlos Castillo SalinasJuan Carlos Castillo Salinas
Juan Carlos Castillo Salinas
EREdgar Ramirez-Ramirez
Edgar Ramirez-Ramirez
Background: Current treatment for Chronic Kidney Disease (CKD) focuses on improving manifestations and delaying progression. Nutritional approaches play a crucial role in CKD management, and various supplements have become available. Ketoanalogues of amino acids (KA), calcum citrate, and inulin have been proposed as suitable supplements, yet their widespread use has been limited due to insufficient evidence. This study aimed to generate general guidance statements on the appropriateness of these supplements through a RAND/UCLA consensus process; Methods: A RAND/UCLA consensus panel was convened to evaluate the appropriateness of these supplements in different clinical scenarios. In this study, we present a subgroup analysis focusing on a panel of eleven clinical nephrologists from among the experts; Results: Supplementation of low protein diets (LPD) and very low protein diets (VLPD) with KA was considered appropriate to reduce manifestations and delay CKD outcomes, supplementation with calcium citrate is considered appropriate to reduce CKD manifestations, and supplementation with inulin is considered appropriate to delay CKD outcomes and manage comorbidities; Conclusions: Based on a combination of clinical experience and scientific evidence , the panel reached a consensus that KA supplementation of LPD and VLPD, calcium citrate, and inulin are appropriate in patients with CKD across various scenarios.

10 December 2024 in Life
Verified
Journal Article
Open access
PDF file
MJMartín Calderón Juárez
Martín Calderón Juárez
LCLABORATORIOS COLUMBIA COMERCIAL
LABORATORIOS COLUMBIA COMERCIAL
KLKarla Guadalupe Del Castillo Loreto
Karla Guadalupe Del Castillo Loreto
Juan Carlos Castillo SalinasJuan Carlos Castillo Salinas
Juan Carlos Castillo Salinas
Claudia LermaClaudia Lerma
Claudia Lerma
The addition of ketoanalogues (KAs) to a low-protein diet has been shown to mitigate the progression of pre-dialysis chronic kidney disease (CKD). The addition of inulin and calcium citrate may add further benefits, given their nephroprotective effects. In this study, we tested the changes in estimated glomerular filtration rate (eGFR), CKD symptoms, body composition, and biochemical parameters after 6 months of diet supplementation with Cetolán III, a combination of KA, inulin, and calcium citrate. We included 76 adult patients diagnosed with CKD stages 3 and 4 and not treated with renal replacement therapy in a retrospective cohort. In this cohort, participants were followed through two clinic visits at 3 and 6 months after diet supplementation. We found a slight increase in eGFR at 3 and 6 months compared with baseline, as well as a decrease in the severity of CDK-related symptoms, fat mass, and muscle mass. We observed only a slight decrease in creatinine and uric acid after 6 months of follow-up. We did not find a remarkable change in anthropometric parameters (e.g., body mass index, waist circumference, and arm muscle area). This observational study suggests that addition of KA, inulin, and calcium citrate to a low protein- diet could be associated with an improvement in eGFR and symptom severity in CKD pre-dialysis.